
GlaxoSmithKline is set to pay £1.58 billion to settle three long-standing legal disputes, including litigation costs for its troubled diabetes …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

